Case Study: a China-based biopharmaceutical company achieves IND approval for its COVID-19 vaccine with FREYR regulatory support

China-based Biopharmaceutical Company secures IND approval with no queries using FREYR

A China-based biopharmaceutical company developing a COVID-19 vaccine faced challenges due to rapidly evolving NMPA guidelines and the operational burden of frequent submissions. They sought FREYR's regulatory guidance and support to navigate these special epidemic policies and maintain critical communication with the authority.

FREYR provided comprehensive regulatory support, organizing consultations with the NMPA and managing rolling submissions with weekly updates. This solution enabled the client to achieve successful IND approval without any queries, securing regulatory clearance under a compressed timeline.

China-based Biopharmaceutical Company